Key result
PIEZO1 gain of function drives cardiomyopathy by disrupting myocardial lipid metabolism via CaMKII-FOXO3 signaling.
Why the study?
The relationship between PIEZO1 mutations and the development of cardiomyopathy remained unclear.
PIEZO1 gain-of-function mutation drives cardiomyopathy by disrupting myocardial lipid metabolism via the Ca2+/CaMKII/FOXO3 pathway, highlighting a novel mechanism beyond iron overload.
Animal study precludes practice change; leaves open PIEZO1 pathway as therapeutic target in human cardiomyopathy.
As a mechanosensitive channel, PIEZO1 translates mechanical stretching of cardiomyocytes into Ca 2+ signaling, underpinning the Frank-Starling law. This mechanism contributes to compensatory responses in heart failure. However, the relationship between PIEZO1 mutations and the development of cardiomyopathy remains unclear. Acute heart failure complicated with severe myocardial iron deposition was identified in the 31-year-old male proband of PIEZO1 D669Y variant. However, PIEZO1 gain-of-function (GOF) mutation D674Y mice and cardiomyocyte-specific Piezo1 overexpression disrupted cardiac function besides iron overload. Using single-cell RNA sequencing, we observed suppression of lipid metabolism pathways in cardiomyocytes with the PIEZO1 GOF mutation, with forkhead box O3 (FOXO3) as a key mediator in lipid metabolism pathways. Specifically, the PIEZO1 GOF mutation increased Ca 2+ levels, leading to calcium- and calmodulin-dependent protein kinase II (CaMKII) activation and subsequent FOXO3 down-regulation. Together, we demonstrate that PIEZO1 GOF mutation contributes to cardiomyopathy by disrupting myocardial lipid metabolism. This study challenges the current clinical focus on iron-related mechanisms in cardiomyopathy and supports PIEZO1 as a potential candidate for future genetic screening for cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2025) studied Cardiomyopathy and acute heart failure (n=1). PIEZO1 gain-of-function mutation was evaluated on Cardiac function and lipid metabolism pathways. PIEZO1 gain-of-function mutation contributes to cardiomyopathy by disrupting myocardial lipid metabolism via CaMKII activation and FOXO3 down-regulation, independent of iron overload.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: